Ready-to-Use Lentiviral Packaging Plasmid Mix (HIV) (Second- and Third-Generation, psPAX2/pMD2.G based)
Product Description
Cellecta’s Ready-to-Use Lentiviral 2-Plasmid Packaging Mix allows production of VSV-G pseudotyped viral particles when co-transfected into packaging cells together with second- or third-generation HIV-based lentiviral vectors.
The Lentiviral Packaging Plasmid Mix is a mixture of the human immunodeficiency virus (HIV) lentiviral packaging plasmid psPAX2 and the pMD2.G plasmid containing VSV-G.
These plasmids provide all the necessary structural, regulatory, and replication proteins required to produce pseudotyped packaged lentiviral expression constructs when co-transfected with an HIV-based lentiviral expression construct (e.g., Cellecta pRSG sgRNA expression construct) into a producer 293T cell line (e.g., ATCC, Cat.# CRL-11268™). Pseudotyped lentiviral particles with VSV-G envelope protein can infect a variety of mammalian or non-mammalian, dividing or non-dividing cells.
Product Citations
- Cascone T et al. (2018) Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.. Cell Metab. 2018 May 1, 27(5):977-987.e4. doi: 10.1016/j.cmet.2018.02.024. Epub 2018 Apr 5. , PMID: 29628419
- Cho JH et al. (2018) RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation. Cell Death Dis. 2018 Jun, 9(6): 587. PMID: 29789542
- Kamijo Y et al. (2018) A novel isolation method for cancer prognostic factors via the p53 pathway by a combination of in vitro and in silico analyses. Oncoscience. 2018 Apr 29, 5(3-4):88-98. PMID: 29854877
- Goodwin JM et al. (2017) Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9. Cell Rep. 2017 Sep 5, 20(10):2341-2356. PMID: 28877469
- Bossi D et al. (2016) In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. PubMed PMID: 27179036.
- Catalog Number
CPCP-K2A-CT - Supplier
Cellecta - Size
- Shipping
Blue Ice
